Search Results 131-140 of 28169 for B cell lymphomas
Follow-up Letters for Subjects in the IRB# 13-001285 "Mayo Clinic Experience with Subjects Diagnosed with Diffuse Large B-cell Lymphoma (DLBCL)" Study. Print ...
The therapy, called axicabtagene ciloleucel (Yescarta), is approved to treat subtypes of lymphoma, including diffuse large B-cell lymphoma, primary mediastinal ...
Clinical Trials · GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 · More about research at Mayo ...
The purpose of this study is to compare epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in ...
A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma · Share · Facebook · Twitter.
Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...
Chimeric antigen receptor (CAR)-T cell therapy trains the immune system cells to fight follicular lymphoma. ... B-cell lymphomas. National Comprehensive Cancer ...
... B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), And Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Print details. Share; Facebook ...
The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) ...
Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.